Abstract
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Xenofon Baraliakos, Joachim Listing, Martin Rudwaleit, Jan Brandt, Rieke Alten, Gerd Burmester, Erika Gromnica-Ihle, Hildrun Haibel, Stephan Schewe, Matthias Schneider, Helmut Sörensen, Henning Zeidler, Sudha Visvanathan, Joachim Sieper and Juergen Braun
The Journal of Rheumatology March 2007, 34 (3) 510-515;
Xenofon Baraliakos
Joachim Listing
Martin Rudwaleit
Jan Brandt
Rieke Alten
Gerd Burmester
Erika Gromnica-Ihle
Hildrun Haibel
Stephan Schewe
Matthias Schneider
Helmut Sörensen
Henning Zeidler
Sudha Visvanathan
Joachim Sieper
In this issue
The Journal of Rheumatology
Vol. 34, Issue 3
1 Mar 2007
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Xenofon Baraliakos, Joachim Listing, Martin Rudwaleit, Jan Brandt, Rieke Alten, Gerd Burmester, Erika Gromnica-Ihle, Hildrun Haibel, Stephan Schewe, Matthias Schneider, Helmut Sörensen, Henning Zeidler, Sudha Visvanathan, Joachim Sieper, Juergen Braun
The Journal of Rheumatology Mar 2007, 34 (3) 510-515;
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Xenofon Baraliakos, Joachim Listing, Martin Rudwaleit, Jan Brandt, Rieke Alten, Gerd Burmester, Erika Gromnica-Ihle, Hildrun Haibel, Stephan Schewe, Matthias Schneider, Helmut Sörensen, Henning Zeidler, Sudha Visvanathan, Joachim Sieper, Juergen Braun
The Journal of Rheumatology Mar 2007, 34 (3) 510-515;